Quick Facts

• RFK Jr. signaled in February that 14 of 19 banned peptides could return to legal compounding status within weeks
• No formal FDA rule change has been published as of March 2026, leaving the peptide market in limbo
• Current FDA ban has created a gray market with consumers buying unregulated peptides from overseas sources

Health and Human Services Secretary Robert F. Kennedy Jr. has promised to reverse FDA restrictions on popular wellness peptides, but the formal regulatory changes have not yet materialized.

In late February 2026, Kennedy appeared on Joe Rogan’s podcast and said he expected the FDA to change the status of “about 14” peptides within a “couple of weeks.” These compounds were moved to the FDA’s Category 2 “do not compound” list in late 2023, effectively banning compounding pharmacies from preparing them.

The affected peptides include BPC-157, ipamorelin, MOTs-C, TB-500, and others popular in wellness circles for claimed benefits like tissue repair and longevity. The FDA cited safety concerns and lack of clinical data when implementing the ban.

“As of this writing, no FDA rule has changed. No Federal Register notice has been issued,” according to regulatory tracking. Emily Hilliard, press secretary for Health and Human Services, declined to provide a timeline for the changes.

The current ban has pushed consumers toward unregulated sources. “It’s all over social media. The black market and the gray market are running amok,” said Scott Brunner, CEO of the Alliance for Pharmacy Compounding.

Dr. Myles Spar, chief medical officer at WndrHLTH, warned about safety risks: “People are getting them from very disreputable sources where they don’t know what’s in them. They’re injecting themselves with things that are potentially dangerous.”

Even if peptides return to Category 1 status, allowing legal compounding under physician supervision, supply chain issues could persist. Brunner estimates it could take months for pharmacies to stock pharmaceutical-grade ingredients and ramp up production.

The peptide market represents significant revenue for compounding pharmacies. The overall peptide market is projected to reach $162.4 billion by 2035, though the wellness segment remains a smaller portion.

Robin Feldman, an FDA law expert at UC Law San Francisco, called the potential change “probably a good move” to bring unregulated peptides “out of the back alley and into the light.”

The compounds cannot be patented, removing incentive for pharmaceutical companies to conduct expensive clinical trials. This leaves patients and physicians operating with limited safety and efficacy data from well-controlled studies.

Dr. Edwin Lee, an endocrinologist who offers peptides in his Florida practice, defended their use: “If you go back in medicine, someone has to be the first one to try Tylenol. There’s always someone who has to do this.”

Industry observers continue monitoring for formal FDA guidance that would allow compounding pharmacies to resume legal peptide preparation under physician supervision.

Read more: The wellness world is eager for RFK Jr.’s promised move on peptides